Kathleen M. Frey, Ph.D.
Affiliations: | 2015- | Pharmaceutical Sciences | Long Island University Pharmacy |
Area:
Medicinal Chemistry, X-Ray crystallography, Structural biology, Molecular modeling, Structure-based drug designGoogle:
"Kathleen Frey"Mean distance: 9.95 | S | N | B | C | P |
Parents
Sign in to add mentor| Amy Christine Anderson | grad student | 2011 | University of Connecticut | |
| (Towards the Understanding of Resistance Mutations in Dihydrofolate Reductase from Methicillin-resistant Staphylococcus aureus.) | ||||
| Karen S. Anderson | post-doc | Yale School of Medicine | ||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hollander K, Chan AH, Frey KM, et al. (2023) Exploring Novel HIV-1 Reverse Transcriptase Inhibitors with Drug Resistant Mutants: A Double Mutant Surprise. Protein Science : a Publication of the Protein Society. e4814 |
| Lange K, Frey KM, Eck T, et al. (2023) Crystal structure of dihydrofolate reductase from the filarial nematode W. bancrofti in complex with NADPH and folate. Plos Neglected Tropical Diseases. 17: e0011303 |
| Frey KM, Bertoletti N, Chan AH, et al. (2022) Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse Transcriptase. Frontiers in Molecular Biosciences. 9: 805187 |
| Tabassum T, Azeem SM, Muwonge AN, et al. (2020) Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors. Current Hiv Research |
| Sasaki T, Gannam ZTK, Kudalkar SN, et al. (2019) Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase. Bioorganic & Medicinal Chemistry Letters |
| Frey KM, Tabassum T. (2019) Current structure-based methods for designing non-nucleoside reverse transcriptase inhibitors Future Virology. 14: 537-544 |
| Azeem SM, Muwonge AN, Thakkar N, et al. (2017) Structure-based methods to predict mutational resistance to diarylpyrimidine non-nucleoside reverse transcriptase inhibitors. Journal of Molecular Graphics & Modelling. 79: 133-139 |
| Frey KM. (2015) Structure-enhanced methods in the development of non-nucleoside inhibitors targeting HIV reverse transcriptase variants. Future Microbiology |
| Gray WT, Frey KM, Laskey SB, et al. (2015) Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance. Acs Medicinal Chemistry Letters. 6: 1075-9 |
| Lee WG, Frey KM, Gallardo-Macias R, et al. (2015) Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase. Bioorganic & Medicinal Chemistry Letters. 25: 4824-7 |